Natco Pharma FY26 Earnings Show Decline Amid Business Transition

Natco Pharma reported consolidated revenue of ₹4,375.9 crore for FY26, a decrease from ₹4,784 crore in FY25. Net profit also saw a decline, falling to ₹1,418.5 crore from ₹1,883.4 crore in the previous fiscal year. The company attributes these results to the inherent cyclicality of its business model, which has historically relied on high-impact 'jackpot' exclusivity products.

For the fourth quarter of FY26, consolidated net revenue was ₹816.9 crore, down from ₹1,287.3 crore in Q4 FY25. Consolidated profit for the quarter stood at ₹269 crore, compared to ₹406 crore in the same period last year.

Reader Takeaway: Declining earnings due to business model shift, but strong cash reserves fuel global M&A plans.

What just happened

Natco Pharma's financial results for the fiscal year ending March 31, 2026, show a reduction in both revenue and net profit compared to the previous year. The company also reported a one-time tax benefit of ₹115 crore from moving to the new tax regime and R&D write-downs of ₹20-30 crore in Q4 FY26.

Why this matters

Shareholders are seeing lower profitability as the company strategically pivots away from 'jackpot' products towards a more stable revenue mix. The guidance for FY27 projects further declines, with revenue expected between ₹3,400-3,500 crore and profit between ₹700-750 crore. However, a strong net cash position of ₹2,400 crore signals a focus on inorganic growth.

The backstory

Natco Pharma has historically capitalized on launching niche generic drugs with market exclusivity. This 'jackpot' model, while rewarding, leads to significant earnings fluctuations. The company's recent performance reflects this, with FY26 figures being lower than FY25.

What changes now

The company is actively seeking acquisitions outside India to build a more consistent revenue base, aiming for 70% of profit from stable sources and 25-30% from specialty products. The Crop Health Sciences division is also being demerged for better focus.

Risks to watch

The U.S. generics market is highly competitive and 'winner-takes-all.' The agrichem business faces ongoing raw material cost inflation. The FY27 guidance indicates a challenging year ahead as the transition takes effect.

Peer comparison

While specific direct peer financial comparisons are not provided in the filing, Natco Pharma operates in the highly competitive pharmaceutical generics market, facing pressure from both domestic and international players. Its strategic shift towards global acquisitions differentiates it from peers focused solely on domestic market expansion or specific product launches.

Context metrics (time-bound)

• FY26 Consolidated Revenue: ₹4,375.9 crore (vs. ₹4,784 crore in FY25)
• FY26 Net Profit: ₹1,418.5 crore (vs. ₹1,883.4 crore in FY25)
• FY27 Revenue Guidance: ₹3,400 - ₹3,500 crore
• FY27 PAT Guidance: ₹700 - ₹750 crore
• Net Cash (Group Level, Q4 FY26): ₹2,400 crore
• Agrichem Revenue FY26: ₹140 crore (vs. ₹60 crore in FY25)
• Semaglutide annualized revenue outlook: ₹75-100 crore.

What to track next

Investors will be closely watching the progress of international expansion in markets like Brazil, Canada, and South Africa. The company's ability to identify and successfully integrate strategic acquisitions for inorganic growth will be crucial. Progress on the Semaglutide product launch and the demerger of the Crop Health Sciences business are also key areas.